Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

B. Lowenberg; J. Beck; C. Graux; W van Putten; H.C. Schouten; L.F. Verdonck; A Ferrant; P. Sonneveld; M. Jongen-Lavrencic; M. von Lilienfeld-Toal; B.J. Biemond; E. Vellenga; D. Breems; H. de Muijnck; R. Schaafsma; G. Verhoef; H. Dohner; A. Gratwohl; T. Pabst; G.J. Ossenkoppele; J. Maertens

doi:10.1182/blood-2009-10-246470

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

B. Lowenberg, J. Beck, C. Graux, W van Putten, H.C. Schouten, L.F. Verdonck, A Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Dohner, A. Gratwohl, T. Pabst, G.J. OssenkoppeleJ. Maertens

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2586-2591
Journal	Blood
Volume	115
Issue number	13
DOIs	https://doi.org/10.1182/blood-2009-10-246470
Publication status	Published - 2010

Access to Document

10.1182/blood-2009-10-246470

Cite this

Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H. C., Verdonck, L. F., Ferrant, A., Sonneveld, P., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B. J., Vellenga, E., Breems, D., de Muijnck, H., Schaafsma, R., Verhoef, G., Dohner, H., Gratwohl, A., Pabst, T., ... Maertens, J. (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), 2586-2591. https://doi.org/10.1182/blood-2009-10-246470

@article{1eda5722d7c04e119e4d65b71fcd5abf,

title = "Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study",

author = "B. Lowenberg and J. Beck and C. Graux and {van Putten}, W and H.C. Schouten and L.F. Verdonck and A Ferrant and P. Sonneveld and M. Jongen-Lavrencic and {von Lilienfeld-Toal}, M. and B.J. Biemond and E. Vellenga and D. Breems and {de Muijnck}, H. and R. Schaafsma and G. Verhoef and H. Dohner and A. Gratwohl and T. Pabst and G.J. Ossenkoppele and J. Maertens",

year = "2010",

doi = "10.1182/blood-2009-10-246470",

language = "Undefined/Unknown",

volume = "115",

pages = "2586--2591",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "13",

}

Lowenberg, B, Beck, J, Graux, C, van Putten, W, Schouten, HC, Verdonck, LF, Ferrant, A, Sonneveld, P, Jongen-Lavrencic, M, von Lilienfeld-Toal, M, Biemond, BJ, Vellenga, E, Breems, D, de Muijnck, H, Schaafsma, R, Verhoef, G, Dohner, H, Gratwohl, A, Pabst, T, Ossenkoppele, GJ & Maertens, J 2010, 'Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study', Blood, vol. 115, no. 13, pp. 2586-2591. https://doi.org/10.1182/blood-2009-10-246470

TY - JOUR

T1 - Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

AU - Lowenberg, B.

AU - Beck, J.

AU - Graux, C.

AU - van Putten, W

AU - Schouten, H.C.

AU - Verdonck, L.F.

AU - Ferrant, A

AU - Sonneveld, P.

AU - Jongen-Lavrencic, M.

AU - von Lilienfeld-Toal, M.

AU - Biemond, B.J.

AU - Vellenga, E.

AU - Breems, D.

AU - de Muijnck, H.

AU - Schaafsma, R.

AU - Verhoef, G.

AU - Dohner, H.

AU - Gratwohl, A.

AU - Pabst, T.

AU - Ossenkoppele, G.J.

AU - Maertens, J.

PY - 2010

Y1 - 2010

U2 - 10.1182/blood-2009-10-246470

DO - 10.1182/blood-2009-10-246470

M3 - Article

C2 - 20103782

VL - 115

SP - 2586

EP - 2591

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -